SelpercatinibMeSH Supplementary Concept

https://ansm.sante.fr/tableau-acces-derogatoire/selpercatinib-20-40-et-80mg-gelule
2024
false
false
false
France
French
selpercatinib
administration, oral
carcinoma, non-small-cell lung
advanced RET fusion-positive non-small cell lung cancer
Product containing only selpercatinib in oral dose form (medicinal product form)
drug information
selpercatinib
pyrazoles
pyridines

---
https://www.has-sante.fr/jcms/p_3505761/fr/retsevmo-selpercatinib-cancer-bronchique-non-a-petites-cellules
2024
false
false
false
France
bronchial neoplasms
adult
treatment outcome
insurance, health, reimbursement
antineoplastic agents
administration, oral
selpercatinib
package leaflet
summary of product characteristics
guidelines for drug use
advanced RET fusion-positive non-small cell lung cancer
RET Fusion Positive
carcinoma, non-small-cell lung
Advanced Lung Non-Small Cell Carcinoma
evaluation of the transparency committee
selpercatinib
carcinoma, non-small-cell lung

---
https://www.has-sante.fr/jcms/p_3442969/fr/retsevmo-selpercatinib-cancer-de-la-thyroide
2023
false
false
false
France
selpercatinib
adult
adolescent
thyroid cancer, medullary
administration, oral
RET Inhibitor
antineoplastic agents
guidelines for drug use
advanced RET fusion-positive thyroid cancer
RET Fusion Positive
evaluation of the transparency committee
selpercatinib
thyroid neoplasms

---
https://www.has-sante.fr/jcms/p_3412892/fr/retsevmo-selpercatinib-cancer-bronchique-non-a-petites-cellules-cbnpc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
advanced RET fusion-positive non-small cell lung cancer
adult
RET Fusion Positive
administration, oral
antineoplastic agents
RET Inhibitor
selpercatinib
evaluation of the transparency committee
selpercatinib
carcinoma, non-small-cell lung

---
https://www.has-sante.fr/jcms/p_3326335/fr/retsevmo-selpercatinib
https://www.has-sante.fr/jcms/p_3326363/fr/decision-n-2022-0082/dc/sem-du-17-mars-2022-du-college-de-la-haute-autorite-de-sante-portant-refus-de-la-demande-d-acces-precoce-de-la-specialite-retsevmo
2022
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
selpercatinib
RET Inhibitor
bronchial neoplasms
carcinoma, non-small-cell lung
adult
evaluation of the transparency committee
selpercatinib

---
https://www.has-sante.fr/jcms/p_3341392/fr/retsevmo-selpercatinib-cancer-de-la-thyroide
https://has-sante.fr/jcms/p_3341401/fr/decision-n-2022-0164/dc/sem-du-19-mai-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-retsevmo
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
administration, oral
RET Inhibitor
adolescent
thyroid cancer, medullary
Advanced Thyroid Gland Medullary Carcinoma
RET Gene Mutation
selpercatinib
evaluation of the transparency committee
thyroid neoplasms
selpercatinib

---
https://www.has-sante.fr/jcms/p_3271751/fr/retsevmo-selpercatinib
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
selpercatinib
administration, oral
RET Inhibitor
protein kinase inhibitors
antineoplastic agents
Proto-Oncogene Proteins c-ret
selpercatinib
Product containing precisely selpercatinib 80 milligram/1 each conventional release oral capsule (clinical drug)
Product containing precisely selpercatinib 40 milligram/1 each conventional release oral capsule (clinical drug)
adult
carcinoma, non-small-cell lung
Advanced Lung Non-Small Cell Carcinoma
adolescent
Advanced Thyroid Gland Medullary Carcinoma
thyroid neoplasms
RET Gene Mutation
carcinoma, non-small-cell lung
thyroid neoplasms
RET Fusion Positive
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
pyrazoles
pyridines

---
https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
pyrazoles
pyrazoles
pyridines
pyridines
RET Inhibitor
RET Inhibitor
protein kinase inhibitors
protein kinase inhibitors
Proto-Oncogene Proteins c-ret
antineoplastic agents
antineoplastic agents
product surveillance, postmarketing
RET Gene Mutation
carcinoma, non-small-cell lung
mutation
carcinoma, non-small-cell lung
bronchial neoplasms
Advanced Lung Non-Small Cell Carcinoma
adult
adolescent
thyroid neoplasms
Advanced Thyroid Gland Medullary Carcinoma
Advanced Thyroid Gland Carcinoma
mutagenicity tests
administration, oral
aged
drug interactions
pregnancy
breast feeding
selpercatinib
drug evaluation, preclinical
selpercatinib
selpercatinib
Product containing precisely selpercatinib 40 milligram/1 each conventional release oral capsule (clinical drug)
Product containing precisely selpercatinib 80 milligram/1 each conventional release oral capsule (clinical drug)
advanced RET fusion-positive non-small cell lung cancer
advanced RET fusion-positive thyroid cancer
Tyrosine Kinase Inhibitors

---
https://www.has-sante.fr/jcms/p_3294124/fr/retsevmo-40-80-mg-selpercatinib-cbnpc
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
selpercatinib
selpercatinib
adult
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
RET Inhibitor
adolescent
thyroid neoplasms
Advanced Thyroid Gland Medullary Carcinoma
Advanced Thyroid Gland Medullary Carcinoma
RET Gene Mutation
RET Fusion Positive
selpercatinib
evaluation of the transparency committee

---